Xolair in Patients With Chronic Sinusitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00117611 |
Recruitment Status :
Completed
First Posted : July 7, 2005
Last Update Posted : September 30, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sinusitis | Drug: Anti-IgE antibody omalizumab or placebo | Phase 4 |
At its most basic level, sinusitis is defined as an inflammation of the lining membrane of the paranasal sinuses. Sinusitis affects all age groups, including 17% of people above the age of 65 years. On the basis of national population surveys and insurance-reimbursement claims, sinusitis is one of the most common health problems in the U.S. Thus, each year, billions of dollars are spent on direct medical costs for the treatment of this enigmatic illness.
Despite the enormous cost of the problem, there are no definite studies of treatment and management. There are some data indicating that intranasal steroids are effective, and recently Nasonex was approved for the treatment of nasal polyps. All other treatments are empirically based.
There is evidence that IgE antibodies play a role in chronic sinusitis. The investigators have shown that total IgE levels correlate with the severity of sinusitis, as assessed by CT scan. Staphylococcus enterotoxins cause local increases in total IgE in over 50% of nasal polyp patients. Allergies occur more frequently in patients with chronic sinusitis than in the general population. Elevations in total IgE have been shown to occur in patients with allergic fungal sinusitis and the levels of total IgE decrease with successful treatment. Thus, the investigators speculate that IgE contributes significantly to the pathogenesis of chronic sinusitis.
The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair, will improve objective and subjective evidence of chronic sinusitis.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 14 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test |
Study Start Date : | July 2005 |
Actual Primary Completion Date : | May 2007 |
Actual Study Completion Date : | January 2009 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
|
Drug: Anti-IgE antibody omalizumab or placebo
given subcutaneously oce or twice monthly depending on dose
Other Name: Xolair or placebo |
Placebo Comparator: 2
placebo administered subcutaneously once or twice monthly
|
Drug: Anti-IgE antibody omalizumab or placebo
given subcutaneously oce or twice monthly depending on dose
Other Name: Xolair or placebo |
- Mucosal thickness on CT scan [ Time Frame: after 6 months of treatment ]
- Rhinosinusitis Disability Index (RSDI)recorded monthly [ Time Frame: 6 months ]
- A specific quality of life (QOL) measure, Sino-Nasal Outcome Test (SNOT 20)recorded monthly [ Time Frame: 6 months ]
- A general health QOL measure (SF-36) [ Time Frame: 6 months ]
- The number of sinusitis exacerbations requiring additional treatment [ Time Frame: 6 months ]
- Nasal peak inspiratory flow [ Time Frame: 6 months ]
- Symptoms of nasal discharge, nasal obstruction, facial pain and altered smell [ Time Frame: 6 months ]
- Nasal lavage eosinophils [ Time Frame: 6 months ]
- Nasal endoscopy score [ Time Frame: 6 months ]
- The University of Pennsylvania Smell Identification Test (UPSIT) [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Chronic sinusitis, as defined by symptoms for greater than 12 weeks, despite treatment
- Paranasal sinus CT scan showing evidence of chronic sinusitis
- Positive skin or RAST test to an inhalant allergen
- Serum total IgE between 30 and 700 International Units/ml
- Body weight less than 150 kg
- Impaired quality of life, as measured by the Rhinosinusitis Disability Index (RSDI)
Exclusion Criteria:
- Women of childbearing potential not using a contraception method(s) (birth control pills, Depo Provera, double barrier) as well as women who are breastfeeding
- Known sensitivity to Xolair
- Patients with severe medical condition(s) that, in the opinion of the investigator, prohibits participation in the study (heart, lung, kidney, neurological, oncologic or liver disease)
- Use of any other investigational agent in the last 30 days
- No measurable disability on the RSDI
- Immunocompromised patients or patients with ciliary disorders

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117611
United States, Illinois | |
The University of Chicago | |
Chicago, Illinois, United States, 60637 |
Principal Investigator: | Robert M Naclerio, MD | University of Chicago |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Chicago |
ClinicalTrials.gov Identifier: | NCT00117611 |
Other Study ID Numbers: |
13916A Q2347s |
First Posted: | July 7, 2005 Key Record Dates |
Last Update Posted: | September 30, 2013 |
Last Verified: | September 2013 |
chronic sinusitis |
Sinusitis Respiratory Tract Infections Infections Paranasal Sinus Diseases Nose Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases |
Omalizumab Antibodies Immunologic Factors Physiological Effects of Drugs Anti-Allergic Agents Anti-Asthmatic Agents Respiratory System Agents |